6月9日中银创新医疗混合C净值增长3.75%，今年来累计上涨60.87%

Group 1 - The core viewpoint of the news is the performance of the Zhongyin Innovation Medical Mixed C Fund, which has shown significant growth in its net value and returns over various time frames [1] - As of June 9, 2025, the latest net value of the fund is 1.9069 yuan, reflecting a growth of 3.75% [1] - The fund's one-month return is 17.56%, six-month return is 43.00%, and year-to-date return is 60.87%, with respective rankings of 159 out of 4686, 36 out of 4533, and 29 out of 4564 [1] Group 2 - The top ten stock holdings of the Zhongyin Innovation Medical Mixed C Fund account for a total of 70.44%, with the largest holdings being Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] - The fund was established on October 30, 2020, and as of March 31, 2025, it has a total scale of 1.454 billion yuan [1] - The fund manager, Zheng Ning, has a background in stock research and has held various positions in asset management companies before joining Zhongyin Fund Management in 2022 [2]